GC
ICPT

Greenlight Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Greenlight Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-81,856
Closed -$2.02M – 71
2020
Q4 		$2.02M Sell
81,856
-18,144
-18% -$601K 0.12% 31
2020
Q3 		$4.15M Buy
+100,000
New +$4.59M 0.34% 26

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Greenlight Capital's ICPT Position: Q1 2021 in Review

Greenlight Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2021, closing a stake of 81,856 shares — an estimated $2.02M sold.

Greenlight Capital first reported a position in ICPT in Q3 2020 and held it in 2 quarters. The position peaked at $4.15M in Q3 2020. 151 funds tracked by Wall St. Rank hold ICPT as of Q1 2021.

  • Greenlight Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Greenlight Capital sold 81,856 Intercept Pharmaceuticals, Inc. shares in Q1 2021, an estimated $2.02M.
  • Greenlight Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2020 and held it in 2 quarters.
  • Greenlight Capital's Intercept Pharmaceuticals, Inc. position peaked at $4.15M in Q3 2020.
  • 151 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2021.

Based on Greenlight Capital's 13F filing for Q1 2021, filed 17 May 2021.